Moneycontrol PRO
UPCOMING EVENT:Attend Traders Carnival Live. 3 days 12 sessions at Rs.1599/-, exclusive for Moneycontrol Pro subscribers. Register now!

Expert panel recommends emergency use of Dr Reddy's Sputnik V vaccine in India

Dr Reddy's which has collaborated with Russia's sovereign fund RDIF conducted the bridge trial for Sputnik V, has applied for emergency use. If approved by DCGI, this will be third vaccine to be available in India.

April 12, 2021 / 05:36 PM IST
Representative image (Reuters)

Representative image (Reuters)

  • bselive
  • nselive
Todays L/H

The Subject Expert Committee (SEC) advising the Drug Controller General of India (DCGI) has recommended Russia's Sputnik V for emergency use authorisation in India.

Dr Reddy's spokesperson confirmed the development. The DCGI will decide on the SEC recommendation.

“RDIF confirms it is awaiting imminently the recommendation by the Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) of India to approve the use of the Russian Sputnik V vaccine against coronavirus in India,” Russia's sovereign fund RDIF said in a statement.

Dr Reddy's, which has collaborated with RDIF, conducted the bridge trial for Sputnik V and has applied for emergency use. If approved by the DCGI, this will be the third vaccine to be available in India.

India is currently using Serum Institute of India's Covishield and Bharat Biotech's Covaxin.


Dr Reddy's earlier said it will import the vaccine initially and later would produce the over 250 million doses of the vaccine. RDIF has also tied up with several Indian contract manufacturers such as Hetero, Panacea Biotec, Strides, Gland Pharma and Virchow Biotech. The deals would put the  potential production capacity of Sputnik V vaccine in India to 1.5 billion doses.  Some of the production will be used for exporting the vaccine.

In India, Dr Reddy's conducted bridge trial inearly 1,600 persons aged between 18 and 99.

Named after the first space satellite of erstwhile Soviet Union, Sputnik V was approved by the regulators in Russia back in August 2020. The vaccine is based on a weakened COVID-19 virus delivering parts of a pathogen that triggers an immune response in the body.

The vaccine has a proven efficacy rate of 91.5 percent.

The cost of Sputnik V, in the international market, is $10 per shot. The vaccine is required to be taken in two doses. It can be stored in dry form at temperature ranging from 2 to 8 degrees.

Sputnik V is now approved for use in 59 countries globally.

Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Apr 12, 2021 03:30 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark